Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

Inclusion Criteria: * Metastatic renal cell carcinoma with a component of clear cell subtype. * Prior first line systemic therapy * At least 1 measurable lesion as per Response Evaluation Criterion in Solid Tumors \[RECIST 1.1\]. * Adequate hematology, liver and kidney functions * Eastern Cooperative Oncology Group \[ECOG\] performance status of 0 or 1. * Life expectancy of ≥12 weeks. * Normotensive or well controlled hypertension (less than/equal to 140/90 mm Hg.) * Negative pregnancy test * Adequate recovery time from prior systemic therapy, surgery or radiation * Willing and able subjects who have signed consent Exclusion Criteria: * More than one prior systemic therapy regimen * Major bowel-penetrating surgery \<4 weeks * Active gastro intestinal bleed in past 3 months * Active peptic ulcer disease in the past 6 months * Current or anticipated use of potent CYP3A4/5 inhibitors * Current or anticipated use of known CYP3A4/5 or CYP1A2 inducers * Requirement for therapeutic warfarin or high dose steroids * Symptomatic or untreated brain metastases * A serious uncontrolled medical disorder or active infection * Pregnant or breastfeeding females * History of another active malignancy * Dementia